Clinical trial
A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With…
NCT00370890 · Chinese University of Hong Kong, Other · Completed
Key facts
| NCT number | NCT00370890 |
|---|---|
| Title | A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy |
| Official title | A Multi-center Prospective Randomized Phase III Trial to Determine the Benefit of Adjuvant Chemotherapy Using Gemcitabine and Cisplatin in Nasopharyngeal Carcinoma Patients With Residual EBV DNA Following Primary Radiotherapy With or Without Concurrent Cisplatin |
| Lead sponsor | Chinese University of Hong Kong, Other |
| Collaborators | Hong Kong Nasopharyngeal Cancer Study Group Limited |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Nasopharyngeal Cancer |
| Intervention type | Drug |
| Interventions | Adjuvant chemotherapy (gemcitabine and cisplatin) |
| Enrollment | 104 |
| Start date | Sep 4, 2006 |
| Primary completion | Oct 26, 2021 |
| Completion | Oct 26, 2021 |
| First posted | Sep 1, 2006 |
| Last update posted | Feb 17, 2022 |
| Countries | Hong Kong |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: